CATALYST PHARMACEUTICALS INC. - COMMON STOCK

22,05

20-февраля-25 15:45:00

15 мин. задержка

Акции

-0,48

-2,13%

Сегодняшний диапазон

21,91 - 22,55

ISIN

N/A

Источник

NASDAQ

Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024

28 май 2024 07:03:00 Источник Nasdaq GlobeNewswire
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update

08 май 2024 15:16:20 Источник Nasdaq GlobeNewswire
Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024

01 май 2024 07:00:01 Источник Nasdaq GlobeNewswire
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024

22 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire
Catalyst Pharmaceuticals Announces Support for the Inaugural Lambert-Eaton Myasthenic Syndrome (LEMS) Awareness Day

28 мар 2024 07:03:00 Источник Nasdaq GlobeNewswire
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium

27 мар 2024 07:03:00 Источник Nasdaq GlobeNewswire
Catalyst Pharmaceuticals Announces AGAMREE® Now Commercially Available in the U.S. for the Treatment of Duchenne Muscular Dystrophy (DMD)

13 мар 2024 06:55:00 Источник Nasdaq GlobeNewswire
Catalyst Pharmaceuticals to Participate at the Barclays 26th Annual Global Healthcare Conference

05 мар 2024 07:03:00 Источник Nasdaq GlobeNewswire
Catalyst Pharmaceuticals Reports Strong Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

28 фев 2024 17:03:23 Источник Nasdaq GlobeNewswire
Catalyst Pharmaceuticals to Present at MDA Clinical & Scientific Conference Details of Registry for Study of Long-Term Safety and Quality of Life in Duchenne Muscular Dystrophy Patients Treated with AGAMREE

27 фев 2024 07:03:00 Источник Nasdaq GlobeNewswire
Catalyst Pharmaceuticals Announces Publication of Santhera Pharmaceutical’s VISION-DMD Vamorolone (AGAMREE®) Study Results in the Peer-Reviewed Journal Neurology

21 фев 2024 08:00:00 Источник Nasdaq GlobeNewswire
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

14 фев 2024 07:03:00 Источник Nasdaq GlobeNewswire
Catalyst Pharmaceuticals, Inc. Announces Closing of Public Offering

09 янв 2024 15:05:13 Источник Nasdaq GlobeNewswire
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock

05 янв 2024 07:02:06 Источник Nasdaq GlobeNewswire
Catalyst Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock

04 янв 2024 15:49:58 Источник Nasdaq GlobeNewswire
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma

18 дек 2023 05:30:03 Источник Nasdaq GlobeNewswire
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies

05 дек 2023 07:03:00 Источник Nasdaq GlobeNewswire
Catalyst Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer and Other Executive Promotions

04 дек 2023 07:03:00 Источник Nasdaq GlobeNewswire
Catalyst Pharmaceuticals To Participate in Piper Sandler 35th Annual Healthcare Conference

16 ноя 2023 07:05:00 Источник Nasdaq GlobeNewswire
Catalyst Pharmaceuticals Reports Strong Third Quarter 2023 Financial Results and Corporate Update

08 ноя 2023 15:11:02 Источник Nasdaq GlobeNewswire

<<
<
1
2
3
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.